1 July 2021 - The July 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The July issue of the Schedule includes a few new/revised listings:

• Guselkumab (Tremfya) - new indication
• Infliximab (Remsima SC) - new formulation
• Ipilimumab (Yervoy) - new indication
• Nivolumab (Opdivo) - new indication
• Pancrelipase (Creon) - new strength
• Progesterone (Utrogestan) - new indication
• Sapropterin dihydrochloride (Kuvan) - new indication
• Tofacitinib citrate (Xeljanz) - new indication

Read Summary of PBS changes